In medtech and healthcare deep tech, capital is often spread too thin across indications, markets and “maybe” opportunities. The result is slow traction, board frustration and value leakage at exit. Sphere helps founders and investors make sharper allocation decisions: Turn noise into a growth thesis We synthesise clinical data, market signals and customer insight into a concise thesis: where each asset can realistically win, on what timeline, and under which conditions. Separate “possible” from “priority” Using that thesis, we rank markets, segments, and partnership routes by impact and feasibility, then deliberately choose what not to pursue in the next 6–24 months. Match BD and marketing to the thesis BD motions, campaigns and web/digital are designed to serve a small number of high-leverage bets, rather than a long list of loosely related ideas. Create investor-grade narratives and artefacts We build the materials and operating rhythms that hold up in ICs and boardrooms: clear rationale, transparent risk, and a line of sight from capital deployed to value created. Outcome Capital, talent and time are concentrated where they can generate meaningful, defensible value – improving both operating performance and eventual exit options.